upifitamab rilsodotin

Phase 2Small molecule

MMersana Therapeutics

upifitamab rilsodotin is one of 9 small molecule programs targeting Cancers. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CancersActive, not recruiting

CancersPhase 2

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Cancers

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Gemzar

Johnson & Johnson

Phase 2

1 3

Gleevec

Novartis

Phase 2

1 4

Mekinist

Novartis

Phase 2

1 5

Tafinlar

Novartis

Phase 2

1 6

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

1 7

Telisotuzumab Adizutecan

AbbVie

Phase 2

1 8

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 9

upifitamab rilsodotin

MMersana Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cancers3 trials

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Completed·MMersana Therapeutics·Phase 1·NCT06517433·62 enrolled

First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

Completed·MMersana Therapeutics·Phase 1·NCT06517485·142 enrolled

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Active, not recruiting·MMersana Therapeutics·Phase 1/2·NCT03319628·523 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for upifitamab rilsodotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — upifitamab rilsodotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for upifitamab rilsodotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mersana Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMersana Therapeutics

upifitamab rilsodotin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cancers3 trials

References

Drug Info

Quick Facts

Related News